Compare Abbott Laboratories (ABT) vs Core and Main Inc (CNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Core and Main Inc — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Core and Main Inc trades at $45.41 (market cap $8.56B). The key difference: Abbott Laboratories is far larger — about 19.5× Core and Main Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| ABT | CNM | |
|---|---|---|
Market Cap | $166.94B | $8.56B |
Sector | Health | Technology |
52-Week High | $136.62 | $66.98 |
52-Week Low | $82.57 | $44.29 |
Enterprise Value | $193.69B | $10.86B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Core & Main (CNM) trades at $45.98, up 2.34% with recent earnings beats driving positive momentum. The stock shows bearish technical signals with resistance at $46-$48, while fundamentals remain solid with 23.73% ROE and consistent revenue growth. Recent Q1 2026 results exceeded expectations at $0.72 EPS versus $0.70 estimate, supported by strong municipal demand and margin expansion initiatives. The company maintains stable cash flow generation with $655M operating cash flow projected for 2026.
CNM presents a mixed outlook with strong fundamentals offset by technical weakness. The bullish analyst consensus (57% buy ratings) and improving debt profile support upside potential, but near-term price pressure from bearish technical indicators requires caution. Key risks include residential market softness and industry supply chain challenges, though the company's reaffirmed FY26 guidance of $7.8-7.9B revenue provides stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
